## Manel Mata-Cases

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8949199/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis. Diabetes Care, 2016, 39, 1987-1995.	8.6	259
2	Control of Glycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes in Primary Care in Catalonia (Spain). Diabetes Care, 2012, 35, 774-779.	8.6	193
3	Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia, 2002, 45, S23-S28.	6.3	182
4	Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings. Lancet Diabetes and Endocrinology,the, 2021, 9, 203-211.	11.4	85
5	Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. European Journal of Health Economics, 2016, 17, 1001-1010.	2.8	77
6	Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007–2013 in Catalonia: a population-based study. BMJ Open, 2016, 6, e012463.	1.9	67
7	Therapeutic inertia in patients treated with two or more antidiabetics in primary care: <scp>F</scp> actors predicting intensification of treatment. Diabetes, Obesity and Metabolism, 2018, 20, 103-112.	4.4	65
8	Fifteen years of continuous improvement of quality care of type 2 diabetes mellitus in primary care in Catalonia, Spain. International Journal of Clinical Practice, 2012, 66, 289-298.	1.7	61
9	Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care. Current Medical Research and Opinion, 2013, 29, 1495-1502.	1.9	54
10	Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area. BMC Nephrology, 2012, 13, 87.	1.8	48
11	Older type 2 diabetic patients are more likely to achieve glycaemic and cardiovascular risk factors targets than younger patients: analysis of a primary care database. International Journal of Clinical Practice, 2015, 69, 1486-1495.	1.7	47
12	Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study. BMJ Open, 2019, 9, e031281.	1.9	47
13	Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). British Journal of Ophthalmology, 2015, 99, 1628-1633.	3.9	40
14	Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. PLoS ONE, 2018, 13, e0198327.	2.5	38
15	Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. Lancet Diabetes and Endocrinology,the, 2022, 10, 112-119.	11.4	37
16	Differences in the Cardiometabolic Control in Type 2 Diabetes according to Gender and the Presence of Cardiovascular Disease: Results from the eControl Study. International Journal of Endocrinology, 2014, 2014, 1-11.	1.5	33
17	miR-10b and miR-223-3p in serum microvesicles signal progression from prediabetes to type 2 diabetes. Journal of Endocrinological Investigation, 2020, 43, 451-459.	3.3	33
18	The Association Between Poor Glycemic Control and Health Care Costs in People With Diabetes: A Population-Based Study. Diabetes Care, 2020, 43, 751-758.	8.6	33

#	Article	IF	CITATIONS
19	Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018. Endocrinologia, Diabetes Y NutriciÓn, 2018, 65, 611-624.	0.3	28
20	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Primary Care Diabetes, 2021, 15, 31-51.	1.8	27
21	Trends in chronic complications of type 2 diabetic patients from Spanish primary health care centres (GEDAPS study): Ten year-implementation of St. Vincent recommendations. Primary Care Diabetes, 2012, 6, 11-18.	1.8	23
22	Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database. Primary Care Diabetes, 2021, 15, 588-595.	1.8	23
23	Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration. Family Practice, 2015, 32, 27-34.	1.9	21
24	Is diabetes mellitus correctly registered and classified in primary care? A population-based study in Catalonia, Spain. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 440-448.	0.8	21
25	Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets. Journal of Diabetes, 2017, 9, 34-44.	1.8	21
26	Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population. European Journal of Preventive Cardiology, 2022, 28, e32-e34.	1.8	21
27	Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts. Diabetologia, 2022, 65, 964-972.	6.3	20
28	Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: A survey research. Diabetes Research and Clinical Practice, 2016, 122, 46-53.	2.8	19
29	Incidence of complications and mortality in a type 2 diabetes patient cohort study followed up from diagnosis in a primary healthcare centre. International Journal of Clinical Practice, 2011, 65, 299-307.	1.7	18
30	Prevalence, clinical features and risk assessment of pre-diabetes in Spain: the prospective Mollerussa cohort study. BMJ Open, 2017, 7, e015158.	1.9	18
31	The impact of a programme to improve quality of care for people with type 2 diabetes on hard to reach groups: The GEDAPS study. Primary Care Diabetes, 2015, 9, 211-218.	1.8	17
32	Understanding the physical, social, and emotional experiences of people with uncontrolled Type 2 diabetes: a qualitative study. Patient Preference and Adherence, 2016, Volume 10, 2323-2332.	1.8	17
33	EpidemiologÃa y control clÃnico de la diabetes mellitus tipo 2 y sus comorbilidades en España (estudio) Tj ETQ	q1 <u> </u>	4314 rgBT /0
34	Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. BMJ Open, 2021, 11, e051237.	1.9	16
35	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes, 2022, 16, 223-244.	1.8	15
36	Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?. Journal of Diabetes Research, 2016, 2016, 1-9.	2.3	14

MANEL MATA-CASES

#	Article	IF	CITATIONS
37	Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovascular Diabetology, 2021, 20, 139.	6.8	13
38	Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 2007–2018. Frontiers in Endocrinology, 2021, 12, 810757.	3.5	13
39	Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y GuÃas ClÃnicas de la Sociedad Española de Diabetes. Revista Clinica Espanola, 2015, 215, 117-129.	0.6	12
40	Decreased iron stores are associated with cardiovascular disease in patients with type 2 diabetes both cross-sectionally and longitudinally. Atherosclerosis, 2018, 272, 193-199.	0.8	12
41	How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. Journal of Diabetes Research, 2019, 2019, 1-9.	2.3	12
42	ls quality of life different between diabetic and non-diabetic people? The importance of cardiovascular risks. PLoS ONE, 2017, 12, e0189505.	2.5	11
43	Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more nonâ€insulin antidiabetic drugs in a realâ€world setting. Diabetes, Obesity and Metabolism, 2019, 21, 1373-1380.	4.4	11
44	Prevalence of pre-diabetes and undiagnosed diabetes in the Mollerussa prospective observational cohort study in a semi-rural area of Catalonia. BMJ Open, 2020, 10, e033332.	1.9	11
45	Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area. Current Medical Research and Opinion, 2019, 35, 1735-1744.	1.9	10
46	Criterios y pautas de terapia combinada en la diabetes tipo 2. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2001, 48, 82-97.	0.8	9
47	High levels of fasting glucose and glycosylated hemoglobin values are associated with hyperfiltration in a Spanish prediabetes cohort. The PREDAPS Study. PLoS ONE, 2019, 14, e0222848.	2.5	9
48	Criterios de control y pautas de tratamiento combinado en la diabetes tipo 2. Actualización 2004. Medicina ClÃnica, 2004, 123, 187-197.	0.6	9
49	Therapeutic Inertia: Still a Long Way to Go That Cannot Be Postponed. Diabetes Spectrum, 2020, 33, 50-57.	1.0	9
50	Impact of implementing electronic clinical practice guidelines for the diagnosis, control and treatment of cardiovascular risk factors: A pre-post controlled study. Atencion Primaria, 2017, 49, 389-398.	1.4	8
51	Prevalencia y control de la diabetes mellitus tipo 2 entre los médicos de Atención Primaria de España. Estudio PRISMA. Endocrinologia, Diabetes Y NutriciÓn, 2017, 64, 265-271.	0.3	8
52	Prediabetes Is Independently Associated with Subclinical Carotid Atherosclerosis: An Observational Study in a Non-Urban Mediterranean Population. Journal of Clinical Medicine, 2020, 9, 2139.	2.4	8
53	Clinical Characteristics and Degree of Glycemic and Cardiovascular Risk Factor Control in Patients with Type 1 Diabetes in Catalonia (Spain). Journal of Clinical Medicine, 2021, 10, 1536.	2.4	8
54	Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. Journal of Clinical Medicine, 2019, 8, 1389.	2.4	7

#	Article	IF	CITATIONS
55	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. Frontiers in Endocrinology, 2021, 12, 708372.	3.5	7
56	Incidence and characteristics of diabetic foot ulcers in subjects with type 2 diabetes in Catalonian primary care centres: An observational multicentre study. Primary Care Diabetes, 2021, 15, 1033-1039.	1.8	6
57	Investigar en diabetes desde una base de datos de atención primaria: la experiencia del Sistema de Información para el Desarrollo de la Investigación en Atención Primaria (SIDIAP). Avances En DiabetologÃa, 2013, 29, 169-174.	0.1	5
58	Impacto de la diabetes mellitus tipo 2 en la calidad de vida de los pacientes tratados en las consultas de atención primaria en España. Atencion Primaria, 2003, 31, 493-499.	1.4	5
59	Mediterranean diet and diabetes risk in a cohort study of individuals with prediabetes: propensity score analyses. Diabetic Medicine, 2022, 39, e14768.	2.3	5
60	Estudio observacional de eficacia y seguridad del cambio de insulina NPH a glargina en atención primaria. Estudio LAURA. Avances En DiabetologÃa, 2013, 29, 137-144.	0.1	4
61	INTEGRA study protocol: primary care intervention in type 2 diabetes patients with poor glycaemic control. BMC Family Practice, 2019, 20, 25.	2.9	4
62	Impact on guidelines: The general practitioner point of view. Diabetes Research and Clinical Practice, 2020, 166, 108091.	2.8	4
63	Improving management of glycaemic control in people with T2DM in primary care: estimation of the impact on the clinical complications and associated costs. BMC Health Services Research, 2020, 20, 803.	2.2	3
64	Mediterranean Diet and Healthy Eating in Subjects with Prediabetes from the Mollerussa Prospective Observational Cohort Study. Nutrients, 2021, 13, 252.	4.1	3
65	The heterogeneity of reversion to normoglycemia according to prediabetes type is not explained by lifestyle factors. Scientific Reports, 2021, 11, 9667.	3.3	3
66	Diabetes Does Not Increase the Risk of Hospitalization Due to COVID-19 in Patients Aged 50 Years or Older in Primary Care—APHOSDIAB—COVID-19 Multicenter Study. Journal of Clinical Medicine, 2022, 11, 2092.	2.4	3
67	Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study. Diabetes Research and Clinical Practice, 2021, 171, 108616.	2.8	2
68	Lactic acidosis associated with metformin in patients with moderate to severe chronic kidney disease: study protocol for a multicenter population-based case-control study using health databases. BMC Nephrology, 2019, 20, 193.	1.8	1
69	Heterogeneity in the association between prediabetes categories and reduction on glomerular filtration rate in a 5-year follow-up. Scientific Reports, 2022, 12, 7373.	3.3	1
70	Consensus on insulin treatment in type 2 diabetes. EndocrinologÃa Diabetes Y Nutrición (English Ed ), 2018, 65, 1-8.	0.2	0
71	327-OR: Multicountry Analysis of Trends in All-Cause Mortality among People with Type 1 Diabetes. Diabetes, 2021, 70, .	0.6	0
72	Cumplimiento de las recomendaciones de ajuste de la dosis de inhibidores DPP4 según la función renal en una base de datos poblacional. Endocrinologia, Diabetes Y NutriciÓn, 2021, 69, 83-83.	0.3	0

#	Article	IF	CITATIONS
73	Diabetes Treatment in Patients with Renal Disease—How Many Are Receiving Contraindicated Drugs?. Diabetes, 2018, 67, 1647-P.	0.6	0
74	Multiple Chronic Comorbidities in a T2DM Mediterranean Population. Diabetes, 2018, 67, 1646-P.	0.6	0
75	Compliance with the DPP-4 inhibitors dose adjustment recommendations based on renal function in a population database. EndocrinologÃa Diabetes Y Nutrición (English Ed ), 2022, 69, 83-91.	0.2	0